Welcome to LustgartenLIVE!, our webinar series designed to bring you face-to-face with the best researchers investigating pancreatic cancer. Moderated by Andrew Rakeman, PhD, Vice President of Research, each webinar in the series will focus on a different aspect of the research funded through your donations.
Hope is on the horizon!
Join Lustgarten Foundation leadership for a special year-end review of the progress we’ve made toward transforming pancreatic cancer into a curable disease—and get a sneak peek into exciting research plans for 2022.
The Best of 2021: Research Highlights, the final LustgartenLIVE! in the inaugural quarterly series, will stream at Noon, Tuesday, Dec. 14.
LustgartenLIVE! was created to give patients, family members, donors and others an opportunity to hear directly from the lead scientists behind our most promising research projects in earlier detection, drug development and personalized medicine. And, because it’s LIVE, you’ll have an opportunity to ask them questions.
The Best of 2021: Research Highlights presenters include:
David Tuveson, MD, PhD
Chief Scientist; Director of the Lustgarten Foundation Dedicated Research Lab at Cold Spring Harbor Laboratory (CSHL) Cancer Center; President, American Association of Cancer Research (AACR)
Elizabeth Jaffee, MD
Chief Medical Advisor; Director, Lustgarten Clinical Accelerator Initiative; Deputy Director of the Sidney Kimmel Comprehensive Cancer Center and Co-director of the Skip Viragh Center for Pancreas Cancer Clinical Research and Patient Care at the Johns Hopkins University School of Medicine
CEO, Lustgarten Foundation
Andrew Rakeman, PhD
VP of Research, Lustgarten Foundation
Past LustgartenLive! Webinars
From the Lab to You: Clinical Advances, September 22, 2021 – World-renowned pancreatic cancer researchers and clinicians, Dr. Tyler Jacks of MIT and Dr. Brian Wolpin of the Dana-Farber Cancer Institute, explain Lustgarten’s critical role in moving research from the lab to the clinic, advancing clinical trials and better therapies. The Foundation established the Clinical Accelerator Initiative (CAI) to shorten the time from clinical trial concept to launch using a Lustgarten-developed process based on the best available science. These “smarter” clinical trials examine cutting-edge biomarkers to observe key indicators of how the treatment is working and will generate large volumes of data scientists can use now and in the future. We are funding three new clinical studies through the CAI focusing on immunotherapy to treat pancreatic cancer. Watch now.
Personalized Medicine: Transforming Treatment Wednesday, June 30, 2021 – Drs. David Tuveson, and Dennis Plenker of the Lustgarten Foundation Dedicated Pancreatic Cancer Research Lab at CSHL, and Dr. Wasif Saif, of Northwell Health Cancer Institute, take you from the clinic to the lab to show you how personalized medicine may transform the future of pancreatic cancer treatment. Watch Now.
Early Detection: The Path Forward Wednesday, April 21, 2021 – Drs. Bert Vogelstein and Elliot Fishman of the Lustgarten Foundation Dedicated Pancreatic Cancer Research Laboratory at Johns Hopkins discuss how a blood test and artificial intelligence may impact earlier detection of pancreatic cancer. Watch now.